Technical Analysis for IMUC - ImmunoCellular Therapeutics, Ltd.

Grade Last Price % Change Price Change
grade F 0.0244 -18.67% -0.01
IMUC closed down 18.67 percent on Friday, March 8, 2019, on 2 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IMUC trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -18.67%
Lower Bollinger Band Walk Weakness -18.67%
Wide Bands Range Expansion -18.67%
Oversold Stochastic Weakness -18.67%

Older signals for IMUC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors. Its lead pipeline product is ICT-107, a therapeutic dendritic cell (DC) vaccine, which is in Phase IIb clinical trial for the treatment of glioblastoma multiforme (GBM) that is a common and lethal type of brain cancer. The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM, as well as solid tumors, including ovarian, pancreatic, and breast cancers; ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells; and ICT-109, a monoclonal antibody product candidate to detect pancreatic and lung cancer in plasma and serum. In addition, it has a differential immunization for antigen and antibody discovery (DIAAD) platform that utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The company is based in Woodland Hills, California.
Medicine Biotechnology Cancer Medical Specialties Oncology Solid Tumors Cancer Immunotherapy Ovarian Cancer Glioblastoma Brain Tumor Lung Cancer Brain Cancer Glioblastoma Multiforme Gynaecology Breast Cancers Gynaecological Cancer Northwest Biotherapeutics
Is IMUC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 0.55
52 Week Low 0.0212
Average Volume 478,251
200-Day Moving Average 0.2447
50-Day Moving Average 0.2001
20-Day Moving Average 0.1643
10-Day Moving Average 0.1098
Average True Range 0.0222
ADX 37.95
+DI 9.6494
-DI 52.6858
Chandelier Exit (Long, 3 ATRs ) 0.1884
Chandelier Exit (Short, 3 ATRs ) 0.0878
Upper Bollinger Band 0.3348
Lower Bollinger Band -0.0062
Percent B (%b) 0.09
BandWidth 207.54717
MACD Line -0.0499
MACD Signal Line -0.0292
MACD Histogram -0.0207
Fundamentals Value
Market Cap 386.7 Thousand
Num Shares 15.8 Million
EPS -6.01
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.03
Resistance 3 (R3) 0.03 0.03 0.03
Resistance 2 (R2) 0.03 0.03 0.03 0.03
Resistance 1 (R1) 0.03 0.02 0.03 0.03 0.03
Pivot Point 0.02 0.02 0.02 0.02 0.02
Support 1 (S1) 0.02 0.02 0.02 0.02 0.02
Support 2 (S2) 0.02 0.02 0.02 0.02
Support 3 (S3) 0.02 0.02 0.02
Support 4 (S4) 0.02